WebCyberlibris ScholarVox est la première bibliothèque numérique communautaire dédiée aux institutions académiques, écoles de commerce et écoles d'ingénieurs. Elle sert dans plus … WebCyberlibris ScholarVox est la première bibliothèque numérique communautaire dédiée aux institutions académiques, écoles de commerce et écoles d'ingénieurs. Elle sert dans …
IONS Earnings Date 2024 Ionis Pharmaceuticals Earnings Forecast
Web13 apr. 2024 · Ionis Pharmaceuticals last announced its quarterly earnings data on February 22nd, 2024. The reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.69. The company earned $152 million during the quarter, compared to analysts' expectations of $160.21 million. Web23 sep. 2024 · ION449 (AZD8233) dosed once monthly via subcutaneous administration, is an investigational medicine that uses Ionis' advanced LI gand- C onjugated A ntisense (LICA) technology platform. It is designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is integrally involved in the regulation of LDL … church of god north webster indiana
A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, …
Web5 apr. 2024 · CARLSBAD, Calif., April 5, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in … WebThe Ionis antisense pipeline. Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our … Web7 mrt. 2024 · For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. church of god nm